

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Peijia Medical Limited**

### **沛嘉醫療有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9996)**

## **VOLUNTARY ANNOUNCEMENT**

### **ACQUISITION OF THE COMPANY'S LICENSING PARTNER JENAVALVE TECHNOLOGY, INC. BY EDWARDS LIFESCIENCES**

This is a voluntary announcement made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) regarding the disposal of equity interests in the Group’s investment in JenaValve Technology, Inc. (“**JenaValve**”). Marvel Finder Limited, a wholly-owned subsidiary of the Company, holds a minority interest of approximately 1.91% of JenaValve’s share capital (calculated on a fully-diluted and as-converted basis), which is recorded as financial assets at fair value through profit or loss in the Company’s consolidated financial statements.

On July 24, 2024, JenaValve has informed the Company that Edwards Lifesciences Corporation, a company listed on the New York Stock Exchange and a global leader of patient-focused innovations for structural heart disease and critical care monitoring, has agreed to acquire JenaValve by way of a merger (the “**Merger**”). Completion of the Merger is subject to the terms and conditions as described in the Merger agreement, including the satisfaction of customary conditions.

JenaValve is a US-based medical device company. In December 2021, the Group obtained the exclusive license to develop, manufacture and commercialize JenaValve Trilogy™ Transcatheter Heart Valve System (THV System) for aortic regurgitation (AR) and aortic stenosis (AS) in the Greater China region (the “**Territory**”). Subsequently, the Company elected to re-brand the technology to be TaurusTrio™ and carried out a multi-center registration clinical trial for severe AR in China (the “**Trial**”). The patient enrollment of the Trial was completed successfully in January 2024.

The Merger shall not affect the Group's exclusive license with JenaValve or the Group's rights to develop and commercialize TaurusTrio™. After completion of the Merger, the Group will maintain the aforementioned exclusive license to develop the THV System for AR and AS in the Territory. The Company believes that the Merger signifies confidence in the future prospects of treating AR with JenaValve's technology.

### **Listing Rules Implications**

The Company is in the process of collecting additional information necessary to assess the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") implications on the Merger, and shall make further announcements under the Listing Rules if and where required.

**THE COMPANY MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET TaurusTrio™ TAVR SYSTEM SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.**

By order of the Board  
**Peijia Medical Limited**  
**Dr. Yi Zhang**  
*Chairman and Executive Director*

Hong Kong, July 25, 2024

*As of the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Dr. Zhiyun YU, Mr. Jifeng GUAN, Mr. Fei CHEN and Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP and Mr. Huacheng WEI as independent non-executive Directors.*